Sugi Predict

Sugi Predict / Compounds / SCHEMBL1735660

SCHEMBL1735660

SCHEMBL1735660

CCCS(=O)(=O)N1C[C@@H](C(=O)N2CCN(c3cc(C)ccc3C)CC2)N(c2ccccc2Cl)C1=O

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 8/20 0.47
▸ TP53 P04637 6/20 0.47
▸ ALDH1A1 P00352 2/20 0.44
▸ NR4A1 P22736 1/20 0.44
▸ ESR2 Q92731 1/20 0.44
▸ TSHR P16473 3/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ USP2 O75604 4/20 0.43
▸ LMNA P02545 3/20 0.42
▸ SMN1; SMN2 Q16637 4/20 0.42
▸ HSD17B10 Q99714 2/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ HTT P42858 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1734747 0.89 TSHR (0.45) MAPTTP53ALDH1A1NR4A1ESR2
SCHEMBL1735627 0.86 MAPT (0.49) MAPTTP53ALDH1A1TSHRMEN1
SCHEMBL1735657 0.86 MAPT (0.44) MAPTTP53ALDH1A1TSHRMEN1
SCHEMBL1735424 0.86 MAPT (0.49) MAPTTP53ALDH1A1TSHRMEN1
SCHEMBL1735421 0.86 MAPT (0.49) MAPTTP53ALDH1A1TSHRMEN1
SCHEMBL1735625 0.86 MAPT (0.49) MAPTTP53ALDH1A1TSHRMEN1
SCHEMBL1735811 0.84 MAPT (0.49) MAPTTP53ALDH1A1NR4A1ESR2
SCHEMBL1736867 0.84 MAPT (0.44) MAPTTP53ALDH1A1NR4A1ESR2
SCHEMBL1736870 0.84 MAPT (0.44) MAPTTP53ALDH1A1NR4A1ESR2
SCHEMBL1735702 0.82 KMT2A (0.45) ALDH1A1MEN1KMT2AHSD17B10CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2142533-B1 IMIDAZOLIDINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-11-16 — — EP claimed
WO-2011069003-A3 METHODS AND SYSTEMS FOR THE TREATMENT OF ANXIETY DISORDERS AND DISORDERS WITH PSYCHOTIC FEATURES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-10-27 — — WO claimed
US-7625902-B2 Imidazolidinone derivatives HOFFMANN-LA ROCHE INC. (US) 2009-12-01 — — US claimed
US-20080242677-A1 IMIDAZOLIDINONE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2008-10-02 — — US claimed
EP-2142533-B1 IMIDAZOLIDINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-11-16 — — EP disclosed
WO-2011069003-A3 METHODS AND SYSTEMS FOR THE TREATMENT OF ANXIETY DISORDERS AND DISORDERS WITH PSYCHOTIC FEATURES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-10-27 — — WO disclosed
EP-2142533-A1 IMIDAZOLIDINONE DERIVATIVES F. Hoffmann-Roche AG (CH) 2010-01-13 — — EP disclosed
US-7625902-B2 Imidazolidinone derivatives HOFFMANN-LA ROCHE INC. (US) 2009-12-01 — — US disclosed
WO-2008119657-A1 IMIDAZOLIDINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2008-10-09 — — WO disclosed
US-20080242677-A1 IMIDAZOLIDINONE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2008-10-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242677-A1 IMIDAZOLIDINONE DERIVATIVES NR1H2, NR1H3, NR1I2 MAPT 4023/4885TP53 4690/4885ALDH1A1 1786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.